Get the Stockscreener App
8.63
11.50%
0.89
Pre-market:
8.99
0.36
+4.17%
Cullinan Therapeutics Inc stock is traded at $8.63, with a volume of 1.34M.
It is up +11.50% in the last 24 hours and up +35.91% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$7.74
Open:
$7.8
24h Volume:
1.34M
Relative Volume:
1.90
Market Cap:
$509.81M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.3388
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+33.80%
1M Performance:
+35.91%
6M Performance:
+10.64%
1Y Performance:
-46.86%
1-Day Range:
$7.74
$8.65
1-Week Range:
$6.50
$8.65
52-Week Range:
$5.68
$17.98
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
8.63 | 457.24M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.90 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.42 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
815.61 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.15 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Does Cullinan Therapeutics Inc. qualify in momentum factor screening2025 Key Highlights & Smart Money Movement Alerts - newser.com
Visual analytics tools that track Cullinan Therapeutics Inc. performance2025 Volatility Report & Weekly Chart Analysis and Guides - newser.com
Is Cullinan Therapeutics Inc. stock a good choice for value investors2025 Performance Recap & Comprehensive Market Scan Insights - newser.com
Cullinan Therapeutics Inc. stock prediction for this week2025 EndofYear Setup & Risk Managed Investment Signals - newser.com
Volume spikes in Cullinan Therapeutics Inc. stock – what they mean2025 Market Sentiment & Daily Profit Focused Screening - newser.com
What momentum shifts mean for Cullinan Therapeutics Inc.Breakout Watch & Advanced Swing Trade Entry Plans - newser.com
What makes Cullinan Therapeutics Inc. stock attractive to growth fundsQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - newser.com
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations - Sahm
Taiho Oncology, Cullinan: Zipalertinib 31.3% Intracranial ORR in NSCLC | CGEM Stock News - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Major Shareholder Buys $3,593,698.00 in Stock - MarketBeat
Lynx1 Capital Management Lp Buys 277,298 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Lynx1 capital buys Cullinan Therapeutics (CGEM) shares worth $9.8m By Investing.com - Investing.com South Africa
Lynx1 capital buys Cullinan Therapeutics (CGEM) shares worth $9.8m - Investing.com
Can machine learning forecast Cullinan Therapeutics Inc. recoveryDay Trade & Daily Profit Focused Screening - newser.com
How to forecast Cullinan Therapeutics Inc. trends using time series2025 Trade Ideas & Real-Time Chart Breakout Alerts - newser.com
Cullinan Therapeutics Inc. stock momentum explainedEarnings Performance Report & Weekly Momentum Stock Picks - newser.com
Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation - Sahm
Cullinan Therapeutics (NASDAQ:CGEM) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Reversal indicators forming on Cullinan Therapeutics Inc. stock2025 Volatility Report & Verified Entry Point Signals - newser.com
Published on: 2025-09-29 10:05:02 - newser.com
Cullinan Therapeutics Inc Stock Analysis and ForecastSupport Level Holds & Free Stock Education Platform for New Investors - earlytimes.in
What analysts say about Cullinan Therapeutics Inc stockCandlestick Pattern Analysis & Small Budget Wealth Building - earlytimes.in
How to use a screener to detect Cullinan Therapeutics Inc. breakoutsQuarterly Market Review & Capital Efficiency Focused Strategies - newser.com
How moving averages guide Cullinan Therapeutics Inc. tradingMarket Performance Report & High Accuracy Investment Signals - newser.com
Published on: 2025-09-26 16:18:03 - newser.com
Multi asset correlation models including Cullinan Therapeutics Inc.July 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Cullinan Therapeutics, Inc. $CGEM Shares Bought by Rhumbline Advisers - Defense World
Using R and stats models for Cullinan Therapeutics Inc. forecastingLong Setup & Entry Point Confirmation Signals - newser.com
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? - sharewise.com
Cullinan Therapeutics (NASDAQ:CGEM) Raised to Hold at Zacks Research - MarketBeat
Cullinan Therapeutics Hits New 52-Week Low at $6.32 - Markets Mojo
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $26.00 Consensus Price Target from Analysts - MarketBeat
Cullinan Therapeutics Hits New 52-Week Low at $5.89 - Markets Mojo
Cullinan Therapeutics Hits New 52-Week Low at $6.24 Amidst Major Decline - Markets Mojo
using r and stats models for cullinan therapeutics inc. forecastingTrade Volume Report & Weekly Market Pulse Updates - newser.com
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.09%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):